Skip to content

Analysis of Emerging Data for the Treatment of Amyloidosis - Post Assessment Survey

Thank you for watching the recent activity 'Analysis of Emerging Data for the Treatment of Amyloidosis'. To assess the success of this activity, we would be grateful if you could answer the following short survey.

If you wish to watch again or share with colleagues, you can watch, here.

This Independent Medical Education programme is supported by an unrestricted educational grant from AstraZeneca.
1.Having taken part in this activity, how would you rate current understanding of the clinical spectrum and cardiac manifestations of ATTR amyloidosis?
2.Having taken part in this activity, how confident are you now in explaining how delayed recognition of ATTR amyloidosis affects disease progression and patient outcomes?
3.Has taking part in this activity improved your familiarity with the design and key real-world findings/studies on ATTR amyloidosis?
4.Has taking part in this activity improved confidence in your ability to interpret the implications for disease presentation and management when reviewing new epidemiological and clinical data on ATTR amyloidosis (e.g., from global registries?
5.Has taking part in this activity made you more likely to integrate realworld evidence into your diagnostic and treatment approach for patients with suspected or confirmed ATTR amyloidosis?
6.Compared to before you took part in activity, to what extent do you agree with the following statement now: ‘Observational data are valuable for improving prognostication and long-term outcomes in patients with ATTR amyloidosis’.